KOPIN CORP
For the period ended Sep 28, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 28, 2024 · Filed Nov 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Unaudited Condensed Consolidated Financial Statements
1. BASIS OF PRESENTATION
The condensed consolidated financial statements of Kopin Corporation as of September 28, 2024 and for the three and nine month periods ended September 28, 2024 and September 30, 2023 are unaudited and include all adjustments, including normal recurring adjustments, that, in the opinion of management, are necessary to present fairly the results of operations for the periods then ended. These condensed consolidated financial statements should be read in conjunction with the Company’s financial statements and notes thereto, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2023. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. As used in this report, the terms “we”, “us”, “our”, “Kopin” and the “Company” mean Kopin Corporation and its subsidiaries, unless the context indicates another meaning.
The condensed consolidated financial statements for the three and nine month periods ended September 28, 2024 and September 30, 2023 include the accounts of Kopin Corporation and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated.
Going Concern
The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company incurred a net loss of $19.7 million and net cash outflows from operations of $15.3 million for the fiscal year ended 2023. The Company incurred a net loss of $41.9 million for the nine months ended September 28, 2024 and net cash outflows from operations of $12.6 million. This net loss of $41.9 million includes an estimated $24.8 million of possible damages related to a jury verdict which is explained below. In addition, the Company has experienced a significant decline in its cash and cash equivalents and marketable securities over the last several years, which was primarily a result of funding operating losses. As described in Note 14 Litigation, on April 22, 2024, a jury verdict was entered against the Company awarding approximately $5.1 million in damages as well as recommending $19.7 million in disgorgement and exemplary damages. On May 22, 2024, the Company filed its Motion for Judgment as a Matter of Law or in the alternative for a New Trial, as well as two submissions arguing that the disgorgement and exemplary damages should not be awarded. That same day, BlueRadios filed motions seeking a permanent injunction prohibiting Kopin from selling any products that incorporate BlueRadios’ trade secrets, over $10 million in pre-judgment interest, and over $10 million in attorneys’ fees and costs. While no final judgment has been issued by the Court, the Court will take that recommendation under advisement and will rule in its final judgment on the final amount after briefing on the issues. Final briefings on the motions were made by the parties on October 29, 2024. The Company is also considering the appeal of any award in a final judgment. The Company had $37.3 million of cash and cash equivalents, restricted cash, and marketable securities at September 28, 2024.
The Company has historical and current negative cash flow from operations and limited liquidity resources. The Company’s current strategy is to continue to invest in its business and raise additional capital through financing activities that may include public offerings and private placements of its common stock, preferred stock offerings, collaborations and licensing arrangements and issuances of debt and convertible debt instruments. Until such time that additional capital can be raised, the Company plans to strategically manage its uncommitted spending, execute its priorities and implement cost saving measures to reduce research and development and general and administrative expenditures which could include minimizing staff costs. The Company may also sell assets and look at other strategic alternatives. There are inherent uncertainties associated with fundraising activities and activities to manage our uncommitted spending and the successful execution of these activities may not be within the Company’s control. There are no assurances that such additional funding will be obtained and that the Company will succeed in its future operations. If the Company is unable to achieve positive cash flows and profitability in the foreseeable future, cannot successfully raise additional capital and implement its strategic plan, or the recommended disgorgement and exemplary damages are not significantly reduced or eliminated in the final order, the Company’s liquidity, financial condition and business prospects will be materially and adversely affected. There is substantial doubt about the Company’s ability to continue as a going concern.
2. ACCOUNTING STANDARDS
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) Number 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”). ASU 2023-09 requires more disaggregated income tax disclosures, including additional information in the rate reconciliation and additional disclosures about income taxes paid. ASU 2023-09 will become effective for the Company for the fiscal year ending December 27, 2025. Early adoption is permitted, and guidance should be applied prospectively, with an option to apply guidance retrospectively. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its condensed consolidated financial statements.
In November 2023, the FASB issued ASU Number 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures” (“ASU 2023-07”). ASU 2023-07 requires disclosure of significant segment expenses that are regularly provided to the chief operating decision maker(s) that are included within each reported measure of segment profit or loss. The guidance also expands disclosure requirements for interim periods, as well as requires disclosure of other segment items, including the title and position of the entity’s chief operations decision maker(s). ASU 2023-07 will become effective for the Company for the fiscal year ending December 28, 2024, and for interim periods starting in the Company’s first quarter of 2025. Early adoption is permitted, and guidance is required to be applied retrospectively. The Company is currently evaluating the impact of the adoption of ASU 2023-07 on its condensed consolidated financial statements.
3. CASH AND CASH EQUIVALENTS, RESTRICTED CASH, AND MARKETABLE SECURITIES
The Company considers all highly liquid, short-term debt instruments with original maturities of three months or less to be cash equivalents.
Restricted cash of approximately $1.1 million is included on the consolidated balance sheet as of September 28, 2024, and represents cash deposited by the Company into a separate account and designated as collateral for a standby letter of credit in the same amount in accordance with a contractual agreement with a vendor. The restricted cash balance at September 28, 2024 and December 30, 2023 is invested in certificates of deposit and money market funds. The restricted cash balance that is invested in certificates of deposit is classified as marketable securities.
Marketable securities consist primarily of commercial paper, medium-term corporate notes, and U.S. Government and agency-backed securities. The Company classifies these marketable securities as available-for-sale at fair value in “Marketable securities, at fair value.” The Company records the amortization of premiums and accretion of discounts on marketable securities in the results of operations.
The Company uses the specific identification method as a basis for determining cost and calculating realized gains and losses with respect to marketable securities. The gross gains and losses realized related to sales and maturities of marketable securities were not material during the three and nine months ended September 28, 2024 and September 30, 2023.
Investments in available-for-sale marketable securities were as follows at September 28, 2024 and December 30, 2023:
| Amortized Cost | Unrealized Losses | Fair Value | ||||
|---|---|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | 2024 | 2023 | |
| U.S. Government and agency-backed securities | $17,256,314 | $4,500,030 | $(1,609) | $(25,655) | $17,254,705 | $4,474,375 |
| Corporate debt | 4,954,096 | 7,750,174 | 3,442 | (32,549) | 4,957,538 | 7,717,625 |
| Total | $22,210,410 | $12,250,204 | $1,833 | $(58,204) | $22,212,243 | $12,192,000 |
The contractual maturity of the Company’s marketable securities was as follows at September 28, 2024:
| Less than One year | One to Five years | Total | |
|---|---|---|---|
| U.S. Government and agency-backed securities | $16,758,720 | $495,985 | $17,254,705 |
| Corporate debt | 4,957,538 | — | 4,957,538 |
| Total | $21,716,258 | $495,985 | $22,212,243 |
4. FAIR VALUE MEASUREMENTS
Financial instruments are categorized as Level 1, Level 2 or Level 3 based upon the method by which their fair value is computed. An investment is categorized as Level 1 when its fair value is based on unadjusted quoted prices in active markets for identical assets that the Company has the ability to access at the measurement date. An investment is categorized as Level 2 if its fair market value is based on quoted market prices for similar assets in active markets, quoted prices for identical or similar assets in markets that are not active, based on observable inputs such as interest rates, yield curves, or derived from or corroborated by observable market data by correlation or other means. An investment is categorized as Level 3 if its fair value is based on assumptions developed by the Company about what a market participant would use in pricing the assets.
The following table details the fair value measurements of the Company’s financial assets:
| Fair Value Measurement at September 28, 2024 Using: | ||||
|---|---|---|---|---|
| Total | Level 1 | Level 2 | Level 3 | |
| Cash equivalents | $12,279,360 | $12,279,360 | $— | $— |
| U.S. Government and agency-backed securities | 17,254,705 | 15,758,720 | 1,495,985 | — |
| Corporate debt | 4,957,538 | 4,957,538 | — | — |
| Equity Investments | 1,097,440 | 223,187 | — | 874,253 |
| Financial instruments, owned, at fair value | $35,589,043 | $33,218,805 | $1,495,985 | $874,253 |
| Fair Value Measurement at December 30, 2023 Using: | ||||
|---|---|---|---|---|
| Total | Level 1 | Level 2 | Level 3 | |
| Cash equivalents | $5,079,605 | $5,079,605 | $— | $— |
| U.S. Government and agency-backed securities | 4,474,375 | — | 4,474,375 | — |
| Corporate debt | 7,717,625 | 7,717,625 | — | — |
| Equity Investments | 4,688,522 | 174,178 | — | 4,514,344 |
| Financial instruments, owned, at fair value | $21,960,127 | $12,971,408 | $4,474,375 | $4,514,344 |
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value because of their short-term nature. If accrued liabilities were carried at fair value, these would be classified as Level 2 in the fair value hierarchy.
Marketable Securities
Corporate debt consists of floating rate notes with a maturity that may be over multiple years but has interest rates that are reset every three months. US government and agency-backed securities consist of high-quality U.S. Government and government-backed (e.g., Fannie Mae, FDIC guaranteed bonds and certificates of deposit) securities. The Company validates the fair market values of the financial instruments above by using discounted cash flow models, obtaining independent pricing of the securities or through the use of a model that incorporates the three-month interest rate, the credit default swap rate of the issuer and the bid and ask price spread of the same or similar investments which are traded on several markets.
Equity Investments
The Company has an investment in RealWear Inc. (RealWear) which had been valued at $5.2 million. In the second quarter of 2023, the Company received shares valued at approximately $0.4 million as payment of royalties. In the second quarter of 2023, the Company reviewed the financial condition and an observable price point in an equity transaction, and as a result, the Company recorded an impairment charge of $3.1 million to reduce the value of the investment to $2.5 million. In both the second and third quarters of 2024, the Company reviewed the financial condition and an observable price point in an equity transaction, and as a result, recorded impairment charges of $0.7 million and $1.1 million, respectively, to reduce the value of the investment to $0.7 million. As of September 28, 2024, the Company owned an approximate 2.8% interest in this investment.
The equity investments categorized as Level 1 at September 28, 2024 were the Company’s equity investments in publicly traded companies that met the categorization requirements for Level 1 classification.
The equity investments that were not remeasured to fair value and therefore did not meet the Level 1, Level 2 or Level 3 classification requirements had a value of $2.0 million at September 28, 2024.
As of September 28, 2024, the Level 3 equity investments include the Company’s investment in RealWear of $0.7 million and the value of an additional equity investment.
5. ACCOUNTS RECEIVABLE, NET
Accounts receivable consisted of the following:
| September 28, 2024 | December 30, 2023 | |
|---|---|---|
| Accounts receivable | $10,248,935 | $10,731,036 |
| Less — allowance for credit losses | (1,015,000) | (1,025,000) |
| Total | $9,233,935 | $9,706,036 |
Changes to the allowance for credit losses for the nine months ended September 28, 2024 were as follows:
| Balance, December 30, 2023 | $1,025,000 |
|---|---|
| Additions | 24,000 |
| Write-offs | (34,000) |
| Balance, September 28, 2024 | $1,015,000 |
6. INVENTORY
Inventories are stated at standard cost adjusted to approximate the lower of cost (first-in, first-out method) or net realizable value and consist of the following at September 28, 2024 and December 30, 2023:
| September 28, 2024 | December 30, 2023 | |
|---|---|---|
| Raw materials | $3,990,155 | $4,785,197 |
| Work-in-process | 1,728,166 | 2,018,421 |
| Finished goods | 837,038 | 798,188 |
| Total | $6,555,359 | $7,601,806 |
7. NET LOSS PER SHARE
Basic net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period less any unvested restricted shares. Diluted net loss per share is calculated using weighted-average shares outstanding and contingently issuable shares, less weighted-average shares reacquired during the period. The net outstanding shares are adjusted for the dilutive effect of shares issuable upon the assumed conversion of the Company’s common stock equivalents, which consist of unvested restricted stock, and outstanding warrants.
The following were not included in weighted-average common shares outstanding-diluted because they are anti-dilutive:
| Three Months Ended | Three Months Ended | Nine months ended | Nine months ended | |
|---|---|---|---|---|
| September 28, 2024 | September 30, 2023 | September 28, 2024 | September 30, 2023 | |
| Non-vested restricted common stock | 5,510,914 | 3,948,417 | 5,510,914 | 3,948,417 |
8. STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION
Registered sale of equity securities
On September 23, 2024, the Company sold 37,550,000 shares of common stock and pre-funded warrants to purchase up to 4,000,000 shares of common stock at a public offering price of $0.64 per pre-funded warrant and received gross proceeds of $27.0 million before deducting underwriting discounts and offering expenses paid by the Company of $1.8 million. The offering price of the pre-funded warrant equals the public offering price per share of the common stock less the $0.01 per share exercise price of each pre-funded warrant.
On September 30, 2024, the Company sold 2,405,000 shares of common stock and received gross proceeds of $1.5 million.
During the three months ended March 30, 2024, the Company sold 3,080,000 shares of common stock for gross proceeds of $7,466,755 (average of $2.42 per share) before deducting broker expenses paid by the Company of approximately $0.2 million, pursuant to the Company’s then effective At-The-Market Equity Offering Sales Agreement, dated as of March 5, 2021 (the “ATM Agreement”) with Stifel, Nicolaus & Company, Incorporated (“Stifel”), as agent. The ATM Agreement terminated in the three months ended March 30, 2024.
On January 27, 2023, the Company sold 17,000,000 shares of common stock and pre-funded warrants to purchase up to 6,000,000 shares of common stock at a public offering price of $0.99 per pre-funded warrant, for gross proceeds of $22.9 million before deducting underwriting discounts and offering expenses paid by the Company of $1.5 million. The offering price of the pre-funded warrant equals the public offering price per share of the common stock less the $0.01 per share exercise price of each pre-funded warrant.
Non-Vested Restricted Common Stock
The fair value of non-vested restricted common stock awards is generally the market value of the Company’s common stock on the date of grant. The non-vested restricted common stock awards require the employee to fulfill certain obligations, including remaining employed by the Company for one, two or four years (the vesting period) and in certain cases also require meeting either performance criteria or the Company’s stock achieving a certain price. For non-vested restricted common stock awards that solely require the recipient to remain employed with the Company, the stock compensation expense is amortized over the anticipated service period. For non-vested restricted common stock awards that require the achievement of performance criteria, the Company reviews the probability of achieving the performance goals on a periodic basis. If the Company determines that it is probable that the performance criteria will be achieved, the amount of compensation cost derived for the performance goal is amortized over the anticipated service period. If the performance criteria are not met, no compensation cost is recognized and any previously recognized compensation cost is reversed.
The Company granted 4,226,320 and 3,296,051 restricted stock units to its employees, executives and the Board of Directors in the nine months ended September 28, 2024 and September 30, 2023, respectively. For fiscal year 2024,1,137,970 shares are part of an incentive program that would vest upon the successful achievement of certain fiscal year 2024 milestones. Through September 28, 2024,99,279 shares were earned upon the achievement of milestones,343,631 were forfeited for failure to meet milestones, and 695,060 may still be earned for achieving milestones in 2024. The fair value of the restricted stock units was based on the fair market value of the Company’s stock on the date of grant. The time-based shares are expensed over the service period and the milestone-based shares are expensed based upon the probability of achievement.
Restricted stock activity for the nine month period ended September 28, 2024 was as follows:
| Shares | Weighted Average Grant Fair Value | |
|---|---|---|
| Balance, December 30, 2023 | 1,931,767 | $1.65 |
| Granted | 4,226,320 | 1.30 |
| Forfeited | (399,644) | 2.50 |
| Vested | (247,529) | 2.00 |
| Balance, September 28, 2024 | 5,510,914 | 1.30 |
Stock-Based Compensation
The following table summarizes stock-based compensation expense within each of the categories below as it relates to non-vested restricted common stock awards for the three and nine months ended September 28, 2024 and September 30, 2023 (no tax benefits were recognized):
| Three Months Ended | Three Months Ended | Nine months ended | Nine months ended | |
|---|---|---|---|---|
| September 28, 2024 | September 30, 2023 | September 28, 2024 | September 30, 2023 | |
| Cost of product revenues | $368,312 | $311,455 | $857,236 | $764,996 |
| Research and development | 308,792 | 214,320 | 569,701 | 553,488 |
| Selling, general and administrative | 535,842 | 432,560 | 1,197,355 | 1,025,298 |
| Total | $1,212,946 | $958,335 | $2,624,292 | $2,343,782 |
Unrecognized compensation expense for non-vested restricted common stock as of September 28, 2024 totaled $4.2 million and is expected to be recognized over a weighted average period of approximatelytwo years.
9. ACCRUED WARRANTY
The Company typically warrants its products against defect for 12 to 18 months, however, for certain products a customer may purchase an extended warranty. A provision for estimated future costs and estimated returns for credit relating to such warranty is recorded in the period when product is shipped and revenue is recognized and is updated as additional information becomes available. The Company’s estimate of future costs to satisfy warranty obligations is based primarily on historical warranty expense experienced and a provision for potential future product failures. Changes in the accrued warranty for the nine months ended September 28, 2024 were as follows:
| Balance, December 30, 2023 | $2,160,000 |
|---|---|
| Additions | 700,000 |
| Claims | (185,000) |
| Balance, September 28, 2024 | $2,675,000 |
Extended Warranties
Deferred revenue represents the purchase of extended warranties by the Company’s customers. The Company recognizes revenue from an extended warranty on the straight-line method over the life of the extended warranty, which is typically 12 to 15 months beyond thestandard 12 to 18-month warranty. The Company classifies the current portion of deferred revenue under Other accrued liabilities in its condensed consolidated balance sheets. At September 28, 2024, the Company had less than $0.1 million of deferred revenue related to extended warranties.
10. INCOME TAXES
The Company recorded a provision for income taxes of approximately $0.1 million in the three and nine months ended September 28, 2024, respectively. The Company recorded a provision for income taxes of less than $0.1 million and approximately $0.1 million in the three and nine months ended September 30, 2023, respectively. As of September 28, 2024, the Company has available for tax purposes U.S. federal net operating loss carryforwards (“NOLs”) of approximately $122.7 million expiring 2024 through 2038 and $107.8 million that have an unlimited carryover period. The Company has recognized a full valuation allowance on its domestic and certain foreign net deferred tax assets due to the uncertainty of the realization of such assets. The Company recognizes both accrued interest and penalties related to its uncertain tax positions related to intercompany loan interest and potential transfer pricing exposure related to its foreign subsidiaries.
11. CONTRACT ASSETS AND LIABILITIES
Contract assets include unbilled amounts typically resulting from sales under contracts when the cost-to-cost method of revenue recognition is utilized and revenue recognized from customer arrangements, including licensing, exceeds the amount billed to the customer, and right to payment is not just subject to the passage of time. Amounts may not exceed their net realizable value. Contract assets are generally classified as current. The Company classifies the noncurrent portion of contract assets under Other assets in its condensed consolidated balance sheets.
Contract liabilities consist of advance payments and billings in excess of cost incurred and deferred revenue.
Net contract assets (liabilities) consisted of the following:
| September 28, 2024 | December 30, 2023 | $ Change | % Change | |
|---|---|---|---|---|
| Contract assets and unbilled receivables —current | $8,274,538 | $3,409,809 | $4,864,729 | 143% |
| Contract liabilities and billings in excess of revenues earned | (268,468) | (916,826) | 648,358 | (71)% |
| Contract liabilities—noncurrent | — | (23,198) | 23,198 | (100)% |
| Net contract assets | $8,006,070 | $2,469,785 | $5,536,285 | 224% |
The $5.5 million increase in the Company’s net contract assets at September 28, 2024 as compared to December 30, 2023 was primarily due to an increase in amounts owed from customers for whom we produce products for defense applications.
In the three and nine months ended September 28, 2024, the Company recognized revenue of less than $0.1 million and $0.9 million, respectively, related to its contract liabilities at December 30, 2023. In the three and nine months ended September 30, 2023, the Company recognized revenue of less than $0.1 million and $0.7 million, respectively, related to its contract liabilities at December 31, 2022.
The Company did not recognize impairment losses on its contract assets in the three or nine months ended September 28, 2024 or September 30, 2023.
Performance Obligations
The Company’s revenue recognition related to performance obligations that were satisfied at a point in time and over time were as follows:
| Three months ended | Three months ended | Nine months ended | Nine months ended | |
|---|---|---|---|---|
| September 28, 2024 | September 30, 2023 | September 28, 2024 | September 30, 2023 | |
| Point in time | 11% | 24% | 16% | 27% |
| Over time | 89% | 76% | 84% | 73% |
Remaining performance obligations represent the transaction price of orders for which work has not been performed and excludes unexercised contract options and potential orders under ordering-type contracts (e.g., indefinite-delivery, indefinite-quantity (“IDIQ”)). As of September 28, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations was $25.4 million which the Company expects to recognize over the next 12 months. The remaining performance obligations represent amounts to be earned under government contracts, which are subject to cancellation.
12. LEASES
The Company enters into operating leases primarily for: real estate, including for manufacturing, engineering, research, administration and sales facilities, and information technology (“IT”) equipment. At September 28, 2024 and December 30, 2023, the Company did not have any finance leases. Approximately all of its future lease commitments, and related lease liability, relate to the Company’s real estate leases. Some of the Company’s leases include options to extend or terminate the lease.
The components of lease expense were as follows:
| Three months Ended | Three months Ended | Nine months Ended | Nine months Ended | |
|---|---|---|---|---|
| September 28, 2024 | September 30, 2023 | September 28, 2024 | September 30, 2023 | |
| Operating lease cost | $218,348 | $216,119 | $651,718 | $648,545 |
At September 28, 2024, the Company’s future lease payments under non-cancellable leases were as follows:
| 2024 (excluding the nine months ended September 28, 2024) | $212,013 |
| 2025 | 766,014 |
| 2026 | 732,610 |
| 2027 | 669,255 |
| 2028 | 201,333 |
| Total future lease payments | 2,581,225 |
| Less imputed interest | (293,289) |
| Total | $2,287,936 |
The Company’s lease liabilities recognized in the Company’s condensed consolidated balance sheet at September 28, 2024 were as follows:
| Operating lease liabilities–current | $653,546 |
|---|---|
| Operating lease liabilities–noncurrent | 1,634,390 |
| Total lease liabilities | $2,287,936 |
Supplemental cash flow information related to leases was as follows:
| Nine months ended | ||
|---|---|---|
| September 28, 2024 | September 30, 2023 | |
| Cash paid for amounts included in the measurement of operating lease liabilities | $649,276 | $741,757 |
Other information related to leases was as follows:
| September 28, 2024 | September 30, 2023 | |
|---|---|---|
| Weighted Average Discount Rate–Operating Leases | 6.80% | 6.06% |
| Weighted Average Remaining Lease Term–Operating Leases (in years) | 3.38 | 4.11 |
13. SEGMENTS AND DISAGGREGATION OF REVENUE
The Company continually monitors and reviews its segment reporting structure in accordance with authoritative guidance to determine if any changes have occurred that would affect its reportable segments. The Company reports under one segment, as its Chief Executive Officer, who is its chief operating decision maker (“CODM”), reviews results on a total company basis.
Total long-lived assets by country at September 28, 2024 and December 30, 2023 were:
| Total Long-lived Assets (in thousands) | September 28, 2024 | December 30, 2023 |
|---|---|---|
| United States | $4,199 | $4,424 |
| United Kingdom | 123 | 244 |
| Total | $4,322 | $4,668 |
The Company disaggregates its revenue from contracts with customers by geographic location and by display application, as it believes this best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors.
During the three and nine months ended September 28, 2024 and September 30, 2023, the Company derived its sales from the following geographies:
| Three months ended · Three months ended · Nine months ended · Nine months ended | ||||||||
|---|---|---|---|---|---|---|---|---|
| September 28, 2024 | September 30, 2023 | September 28, 2024 | September 30, 2023 | |||||
| (In thousands, except percentages) | Revenue | % of Total | Revenue | % of Total | Revenue | % of Total | Revenue | % of Total |
| United States | $12,612 | 95% | $9,879 | 94% | $33,352 | 93% | $27,788 | 88% |
| Other Americas | — | — | — | — | 5 | — | 5 | — |
| Total Americas | 12,612 | 95 | 9,879 | 94 | 33,357 | 93 | 27,793 | 88 |
| Asia - Pacific | 382 | 3 | 363 | 3 | 1,632 | 5 | 2,956 | 9 |
| Europe | 326 | 2 | 356 | 3 | 700 | 2 | 1,068 | 3 |
| Total Revenues | $13,320 | 100% | $10,598 | 100% | $35,689 | 100% | $31,817 | 100% |
During the three and nine months ended September 28, 2024 and September 30, 2023, the Company derived its sales from the following display applications:
| Three months ended | Three months ended | Nine months ended | Nine months ended | |
|---|---|---|---|---|
| (In thousands) | September 28, 2024 | September 30, 2023 | September 28, 2024 | September 30, 2023 |
| Defense | $10,434 | $4,996 | $29,095 | $16,482 |
| Industrial | 489 | 310 | 1,883 | 2,118 |
| Consumer | — | 200 | 25 | 573 |
| R&D | 2,268 | 4,956 | 4,338 | 11,737 |
| License and royalties | 129 | 136 | 348 | 907 |
| Total Revenues | $13,320 | $10,598 | $35,689 | $31,817 |
14. LITIGATION
The Company may engage in legal proceedings arising in the ordinary course of business. Claims, suits, investigations and proceedings are inherently uncertain and it is not possible to predict the ultimate outcome of such matters and our business, financial condition, results of operations or cash flows could be affected in any particular period.
BlueRadios, Inc. v. Kopin Corporation, Civil Action No. 16-02052-JLK (D. Col.):
On August 12, 2016, BlueRadios, Inc. (“BlueRadios”) filed a complaint in the U.S. District Court for the District of Colorado, alleging that the Company breached a contract between it and BlueRadios concerning a joint venture between the Company and BlueRadios to design, develop and commercialize micro-display products with embedded wireless technology referred to as “Golden-i,” breached the covenant of good faith and fair dealing associated with that contract, breached its fiduciary duty to BlueRadios, and misappropriated trade secrets owned by BlueRadios in violation of Colorado law (C.R.S. § 7-74-104(4)) and the Defend Trade Secrets Act (18 U.S.C. § 1836(b)(1)). BlueRadios further alleged that the Company was unjustly enriched by its alleged misconduct, BlueRadios is entitled to an accounting to determine the amount of profits obtained by the Company as a result of its alleged misconduct, and the inventorship on at least ten patents or patent applications owned by the Company need to be corrected to list BlueRadios’ employees as inventors and thereby list BlueRadios as co-assignees of the patents. BlueRadios seeks monetary, declaratory, and injunctive relief, including for alleged non-payment of engineering retainer fees.
On October 11, 2016, the Company filed its Answer and Affirmative Defenses. The parties completed expert depositions on November 15, 2019. On December 2, 2019, the Company filed a Motion for Partial Summary Judgment requesting the Court dismiss counts 2-7 in their entirety and counts 1 and 8 in part. BlueRadios also filed a Motion for Partial Summary Judgment alleging it is the co-owner of U.S. Patent No. 8,909,296. Responses to the Motions for Partial Summary Judgment were filed on January 15, 2020, and replies were filed on February 19, 2020. On September 25, 2020, the Court denied BlueRadios’ Motion for Partial Summary Judgment. On August 3, 2022, the Court granted the Company’s Motion for Partial Summary Judgment by dismissing counts 3, 6, 7, the claim for punitive damages under count 2, and count 8 as it relates to patent applications and by denying the motion as it relates to counts 1, 4, and 5, and the remainder of counts 2 and 8. The Court also ordered discovery reopened for certain limited purposes. A trial date was set by the Court for January 22 to February 5, 2024 but then re-scheduled for March 20 to April 16. On Monday, April 22, 2024, after a four week trial, a jury verdict was entered finding for BlueRadios and awarding approximately $5.1 million in damages as well as recommending $19.7 million in disgorgement and exemplary damages. While no final judgment has been issued by the Court, the Court will take that recommendation under advisement and will rule in its final judgment on the final amount after post-trial briefing. On May 22, 2024, the Company filed its Motion for Judgment as a Matter of Law or in the alternative for a New Trial, as well as two submissions arguing that the disgorgement and exemplary damages should not be awarded. That same day, BlueRadios filed motions seeking a permanent injunction prohibiting Kopin from selling any products that incorporate BlueRadios’ trade secrets, over $10 million in pre-judgment interest, and over $10 million in attorneys’ fees and costs. Briefing on those issues concluded on June 26, 2024. On September 25, 2024, the Company filed a supplemental brief on issue preclusion arguing that BlueRadios’ claims were untimely because of findings of fact made inBlueRadios, Inc. v. Hamilton, Brook, Smith & Reynolds, P.C., No. 1:21-cv-10488-DJC, ECF 268 (D. Mass. Sept. 18, 2024). That supplemental briefing concluded on October 29, 2024. The Company is currently considering an appeal of any final judgment. The Company accrued $5.1 million in damages as well as $19.7 million in disgorgement and exemplary damages, which was recorded in the financial statements for the nine months ended September 28, 2024.
15. RELATED PARTY TRANSACTIONS
The Company may from time to time enter into agreements with stockholders, affiliates and other companies engaged in certain aspects of the display, electronics, optical and software industries as part of its business strategy. In addition, the wearable computing product market is relatively new and there may be other technologies the Company needs to purchase from affiliates to enhance its product offering.
On January 5, 2023, the Company entered into a Technology License Agreement and an Asset Purchase Agreement (the “LST Agreements”) with Lightning Silicon Technology, Inc. (“LST”). Pursuant to the LST Agreements, the Company issued a license to LST for certain technology associated with its Organic Light Emitting Technology, transferred in-process development contracts with two customers and accounts receivables that the Company had previously determined were not collectible. The technology license agreement provides for Kopin to transfer certain patents to LST if LST achieves certain milestones, however upon transfer Kopin will receive a license to the technology. To the extent LST makes improvements to the technology licensed from Kopin, Kopin will receive a license for these improvements for certain markets. Kopin is not obligated to provide any additional funding support to LST. As consideration for the transaction, the Company received 18,000,000 common shares representing a 20.0% equity stake in LST. The Company will also receive a royalty based on unit sales of products that utilize the technology licensed. Drs. John Fan, the Company’s former President and CEO and former Chairman of the Board, Boryeu Tsaur, a former Executive Vice President of the Company and Hong Choi, the Company’s former Chief Technology Officer terminated their employment with the Company and became investors in and members of the management team of LST. Dr. Fan is the Founder of LST. As a result of this transaction, in 2022 the Company wrote off the two operating lease assets associated with facilities used for the development of the Company’s organic light emitting diode (OLED) products. The Company has recorded its investment in LST at $0 as of September 28, 2024 and December 30, 2023.
During the three and nine months ended September 28, 2024 and September 30, 2023, the Company had the following transactions with related parties:
| Three months ended | ||||
|---|---|---|---|---|
| September 28, 2024 | September 30, 2023 | |||
| Sales | Purchases | Sales | Purchases | |
| RealWear, Inc. | $94,854 | — | $135,918 | $— |
| HMDmd, Inc. | 76,918 | — | 349,420 | — |
| Solos Technology | 33,288 | — | — | — |
| Lightning Silicon Technology, Inc. | 924 | 6,650 | — | 208,933 |
| $205,984 | 6,650 | $485,338 | $208,933 | |
| Nine months ended | ||||
|---|---|---|---|---|
| September 28, 2024 | September 30, 2023 | |||
| Sales | Purchases | Sales | Purchases | |
| RealWear, Inc. | $311,994 | 10,550 | $905,564 | $— |
| HMDmd, Inc. | 299,177 | — | 852,175 | — |
| Vuzix Corp | — | 11,905 | — | — |
| Solos Technology | 33,288 | — | — | — |
| Lightning Silicon Technology, Inc. | 3,158 | 170,850 | — | 416,988 |
| $647,617 | 193,305 | $1,757,739 | $416,988 | |
At September 28, 2024 and December 30, 2023, the Company had the following receivables from and payables to related parties:
| September 28, 2024 | December 30, 2023 | |||
|---|---|---|---|---|
| Receivables | Payables | Receivables | Payables | |
| RealWear, Inc. | $94,854 | $— | $94,902 | $— |
| HMDmd, Inc. | 101,922 | — | 15,000 | — |
| Solos Technology | 33,288 | — | — | — |
| Lightning Silicon Technology, Inc. | 41 | — | 35,013 | 97,600 |
| $230,105 | $— | $144,915 | $97,600 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.